ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation

Lung cancer is the leading cause of cancer mortality in the United States, with an overall five-year survival rate of ~16%. Non-small cell lung cancer (NSCLC) accounts for ~80% of all lung cancer cases, and the majority (40%) of these are adenocarcinomas. Loss of function point mutations in TP53 (46...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Aaditya, Gu, Jing Jin, McKernan, Courtney M., Xu, Xia, Pendergast, Ann Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443011/
https://www.ncbi.nlm.nih.gov/pubmed/30956771
http://dx.doi.org/10.18632/oncotarget.26740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443011/
https://www.ncbi.nlm.nih.gov/pubmed/30956771
http://dx.doi.org/10.18632/oncotarget.26740

Ejemplares similares